Volume | 19,629 |
|
|||||
News | - | ||||||
Day High | 5.22 | Low High |
|||||
Day Low | 4.915 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aprea Therapeutics Inc | APRE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.08 | 4.915 | 5.22 | 5.19 | 5.299 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
145 | 19,629 | $ 5.00 | $ 98,160 | - | 2.78 - 8.8465 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:03 | 6 | $ 4.97 | USD |
Aprea Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
19.39M | 3.74M | - | 583k | -14.29M | -3.82 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aprea Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APRE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.29 | 5.30 | 4.915 | 5.09 | 8,700 | -0.10 | -1.89% |
1 Month | 5.13 | 5.90 | 4.9001 | 5.40 | 9,009 | 0.06 | 1.17% |
3 Months | 8.40 | 8.40 | 4.9001 | 6.49 | 31,541 | -3.21 | -38.21% |
6 Months | 3.67 | 8.8465 | 3.50 | 6.21 | 22,516 | 1.52 | 41.42% |
1 Year | 3.40 | 8.8465 | 2.78 | 4.75 | 26,000 | 1.79 | 52.65% |
3 Years | 83.00 | 156.00 | 2.78 | 79.88 | 612,386 | -77.81 | -93.75% |
5 Years | 309.20 | 1,062.20 | 2.78 | 118.28 | 551,799 | -304.01 | -98.32% |
Aprea Therapeutics Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |